REG - Novacyt S.A. - Publication of Annual Report and AGM voting

Novacyt SAAnnouncement

01/06/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220601:nRSA4810Na&default-theme=true

RNS Number : 4810N  Novacyt S.A.  01 June 2022

Novacyt S.A.

 

("Novacyt", the "Company" or the "Group")

 

Publication of Annual Report and AGM voting

 

Paris, France and Camberley, UK - 1 June 2022 - Novacyt (EURONEXT GROWTH:
ALNOV; AIM: NCYT), an international specialist in clinical diagnostics,
announces that the Company's Annual Report and Accounts ("Annual Report") for
the year ended 31 December 2021 has been published and uploaded to the
Company's website. The Annual Report has been posted to all shareholders that
hold ordinary shares through CREST Depository Interests (CDIs).

 

The Company's Annual General Meeting ("AGM") will be held as an open online
meeting at 1pm BST/2pm CEST on Tuesday, 21 June 2022. As usual, and in
accordance with French corporate law, the AGM comprises both ordinary and
extraordinary general meetings.

 

The Notice of AGM and a Form of Proxy are available on the Company's website,
together with AGM registration details and a video explaining the voting
process to shareholders. All materials can be found at
www.novacyt.com/investors (http://www.novacyt.com/investors) .

 

Shareholders can register for the AGM and access the online meeting by
visiting https://novacyt.eventcaster.co.uk (https://novacyt.eventcaster.co.uk)
. Registrations must include an electronic signature and be accompanied by
proof of shareholding by 10.59pm BST/11.59pm CEST on Thursday 16 June 2022.

 

Shareholders are strongly encouraged to submit their proxy votes either by
post, email or vote electronically in accordance with the instructions in the
Notice of AGM.

 

Shareholders can vote in advance of the AGM until 3pm BST/4pm CEST on Monday
20 June 2022 by:

 

·      Downloading a copy of the Proxy voting form from www.n
(http://www.novacyt.com/investors) ovacyt.com/investors
(http://www.novacyt.com/investors) for completion and return to
investor.relations@novacyt.com (mailto:investor.relations@novacyt.com)
together with evidence of their holding.

·      Voting on-line using the AGM portal
https://novacyt.eventcaster.co.uk
(https://eur02.safelinks.protection.outlook.com/?url=https%3A%2F%2Fnovacyt.eventcaster.co.uk%2Faccess%2Flogin&data=05%7C01%7Cmandy.cowling%40novacyt.com%7Caa7b9acfe8684748cffc08da3da15a5a%7C7f86b855a6074882a2cf7ae773bd7869%7C0%7C0%7C637890060459264621%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000%7C%7C%7C&sdata=a6oCzNZEhwj4%2FrJ9YxdQ9H879PyYHYPQ2JwChUa9PDA%3D&reserved=0)
together with an electronic signature and proof of shareholding.

·      Voting on-line using the Votaccess portal
http://www.actionnaire.cic-marketsolutions.eu
(http://www.actionnaire.cic-marketsolutions.eu)  if securities held on
Euronext Growth are registered with any of the following banks: CIC, Natixis,
Société Générale, Caceis, Crédit Agricole, BP2S, BNP Retail, Bourse
Direct, ODDO, Rothschild Martin Maurel, Procapital, Citibank, Deutsche Bank or
JP Morgan.

 

Under French law, for the AGM and EGM meetings to be quorate at the first
attempt, at least 20% of shareholders must vote on the ordinary resolutions
and 25% of shareholders must vote on the extraordinary resolutions.

 

Following registration and proof of shareholding, shareholders will be able to
virtually attend the AGM and vote online during the meeting if they wish.
Following the meeting, a recording of the AGM will be available on the
Company's website at www.novacyt.com/investors
(http://www.novacyt.com/investors) . Shareholders who have already voted
(through a proxy, using the AGM or Votaccess portals) will be allowed to
attend the AGM but will not be able to vote twice.

 

- End -

 

Contacts

Novacyt SA

David Allmond, Chief Executive Officer

James McCarthy, Chief Financial Officer

+44 (0)1276 600081

 

SP Angel Corporate Finance LLP (Nominated Adviser and Broker)

Matthew Johnson / Charlie Bouverat (Corporate Finance)

Vadim Alexandre / Rob Rees (Corporate Broking)

+44 (0)20 3470 0470

 

Numis Securities Limited (Joint Broker)

Freddie Barnfield / James Black / Duncan Monteith

+44 (0)20 7260 1000

 

Allegra Finance (French Listing Sponsor)

Rémi Durgetto / Yannick Petit

+33 (1) 42 22 10 10

r.durgetto@allegrafinance.com (mailto:r.durgetto@allegrafinance.com) ;
y.petit@allegrafinance.com (mailto:y.petit@allegrafinance.com)

 

FTI Consulting (International)

Victoria Foster Mitchell / Alex Shaw

+44 (0)20 3727 1000

victoria.fostermitchell@fticonsulting.com
(mailto:victoria.fostermitchell@fticonsulting.com) /
Alex.Shaw@fticonsulting.com (mailto:Alex.Shaw@fticonsulting.com)

 

FTI Consulting (France)

Arnaud de Cheffontaines

+33 (0)147 03 69 48

arnaud.decheffontaines@fticonsulting.com
(mailto:arnaud.decheffontaines@fticonsulting.com)

 

About Novacyt Group

The Novacyt Group is an international diagnostics business generating an
increasing portfolio of in vitro and molecular diagnostic tests. Its core
strengths lie in diagnostics product development, commercialisation, contract
design and manufacturing. The Company supplies an extensive range of
high-quality assays and reagents worldwide. The Group directly serves
microbiology, haematology and serology markets as do its global partners,
which include major corporates.

 

For more information, please refer to the website: www.novacyt.com
(http://www.novacyt.com)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCBFLLXLELEBBF